Therapeutic Benefits

An image of hexagonal molecules with herbs inside each hexagon and a microscope off to the left to indicate research of the herbs.

 

Synergy BioNaturals pipeline currently includes three condition-specific CBD formulations for stress, pain, and sleep. 

 

β-Calmed (Stress)

 

SBN’s stress-relief formula, which includes Broad-Spectrum CBD, promotes relaxation by supporting a healthy stress response. Research has shown that a disruption in the body’s response to physical and emotional stressors contributes to anxiety.  

 

β-Calmed works by aiding the body’s inhibitory actions on the stress response and supporting systemic balance. 

 

Anxiety involves large interneuronal networks that can be difficult to manage in a state of excitability. Reducing the generation and accessibility of large constellations of brain networks promotes calm and relaxation.  

 

Synergy BioNaturals β-Calmed Ingredients

 

CBD Broad Spectrum elevates the endogenous cannabinoid Anandamide which has been shown to increase connections between different areas of the brain such as the limbic system (seat of emotions & memory) and the prefrontal cortex (logic, planning) allowing better emotional processing of anxiety based memories.  

 

Shoden® Ashwagandha provides the bioactive polyphenolic compounds glycowithanolides, which can protect the brain from oxidative stress by increasing the activity of endogenous antioxidant enzymes. Shoden® Ashwagandha is a powerful adaptogen that can help the body adapt and recover from stress.

 

Suntheanine® has been shown to promote Alpha wave activity in higher brain regions. Suntheanine® promotes a healthy stress response in the Hypothalamic Pituitary Adrenal Axis (HPA) by supporting the anxiolytic effects of the neurotransmitter GABA.

 

Myrcene is a natural muscle relaxant that induces the “couch-lock” sedative effect. Myrcene synergizes with other terpenes to calm the body, which promotes calm. 

 

β-Caryophyllene combats chronic stress by crossing the blood-brain barrier and binding to the CB2 receptor activating the endocannabinoid system.  

 

β-Relieved (Pain) 

 

SBN’s pain relief formula, which includes Broad Spectrum CBD, works to address the underlying causes of chronic inflammation and pain. β-Relieved is a safe and effective alternative to NSAIDs and other over the counter medications. 

 

β-Relieved combines the wisdom of ancient healing systems with modern advances in biochemistry to activate the body’s anti-inflammatory pathways. The synergy of phytochemicals, cannabinoids, and terpenes work naturally within the body to support health & wellness. 

 

Inhibiting inflammation involves modulating the activity of pro-inflammatory enzymes such as 5-Lipoxygenase and TNF-a. The synergy between compounds has a greater biological effect than the action of isolated ingredients. 

 

The immune system uses proinflammatory and anti-inflammatory cytokines to coordinate its activities. An anti-inflammatory action can naturally modulate inflammatory pathways, changing how the immune system communicates with itself.  

 

Synergy BioNaturals β-Relieved Ingredients  

 

CBD Broad Spectrum (Cannabidiol) has been shown to activate TRPV1 Vanilloid receptors, which play an essential role in pain perception, body temperature, and inflammation. Activation of TRPV1 shifts how the brain processes noxious stimuli. 

 

CBC (Cannabichromene) is a lesser-known cannabinoid that modulates pain by inhibiting endocannabinoid degradation. 

 

CBG (Cannabigerol) has been shown to prevent oxidative induced inflammation by modulating cytoprotective antioxidant transcription factors such as nuclear factor erythroid 2-related factor 2 (Nrf2).   

 

Boswellia as 5-Lox® has shown in studies to inhibit the activity of 5-lipoxygenase and TNF-a, halting the inflammatory driven destruction of soft tissues.

 

Turmeric Extract as BCM95® has exhibited in research to inhibit chronic pain by shutting off the “master inflammatory switch” nuclear factor kappa-b (NF-kB), which activates over 150 genes involved in systemic inflammation.

 

Ginger 5mg Shogoals not only increases the bioavailability of Boswellia and Turmeric but ginger aids in the treatment of inflammatory driven conditions such as osteoarthritis and rheumatoid arthritis by inhibiting the biosynthesis of pro-inflammatory hormones.

 

a-pinene is a powerful anti-inflammatory that is able to inhibit many proinflammatory enzymes involved in systemic inflammation. A-pinene has shown an ability to block NF-kb “the master inflammatory switch,” which activates over 150 genes that encode proinflammatory proteins and enzymes.

 

Myrcene is a natural muscle relaxant that induces the “couch-lock” sedative effect when synergized with other terpenes such as Limonene. Myrcene has been shown to exert its anti-inflammatory benefits by inhibiting the activity of the eicosanoid PGE2.

 

d-Limonene synergizes with the terpene myrcene increasing its anti-inflammatory, anti-oxidative, and anti-proliferative benefits.

 

β-Caryophyllene combats chronic low-level inflammation by modulating adaptive immune cell lines. β-Caryophyllene is highly lipophilic, giving it the unique ability to cross the blood-brain barrier and bind to the CB2 receptor activating the endocannabinoid system. 

 

β-Rested (Sleep)

 

SBN’s sleep formula promotes the natural stages of sleep by first reducing the time it takes to fall asleep. The nutraceuticals in β-Rested such as Valerian Root and CBD, support the inhibitory actions of adenosine and GABA, which modulate neuronal pathways that promote wakefulness and prevent sleep. 

 

β-Rested allows the brain to get into slow-wave sleep (REM), which is essential for cellular maintenance, repair, and renewal. Anxiety often underlies sleep disorders disrupting neuronal excitation and inhibition. 

 

Blood sugar levels elevate during times of emotional distress to promote wakefulness. Insufficient sleep lowers stress thresholds, which increase anxiety, stimulating a sympathetic fight or flight stress response that promotes arousal. β-Rested promotes Alpha wave activity in higher brain regions reducing the time it takes to fall asleep while naturally initiating the natural cycles of sleep.

 

 

β-Rested Ingredients

 

CBD Broad Spectrum has been shown in studies to inhibit the uptake of the neuromodulator adenosine, which plays a fundamental role in suppressing arousal and inducing sleep.

 

Suntheanine® has been shown in studies to bind to glutamate receptors, inhibiting excitatory activity in the brain. Suntheanine® is noticeable within 30 mins of ingestion and exerts a calming effect by supporting the activity of GABA. 

 

Valerian (Valerenic Acid 2.4mg 0.8%) has been used since antiquity to treat sleep disorders, and modern research has validated its mechanism of action, which is the activation of the GABA receptors involved in inhibiting the firing of neurons.

 

5-Hydroxytryptophan (5-HTP) is extracted from the seed of an African plant known as Griffonia Simplicifolia. 5-HTP is taken up by the body and enzymatically converted in the brain to serotonin. Serotonin is used to create the sleep hormone melatonin, which influences sleep-wake cycles (circadian rhythms).

 

β-Caryophyllene is highly lipophilic, giving it the unique ability to cross the blood-brain barrier and bind to the CB2 receptor, where it provides anxiolytic benefits.

 

Linalool is a calming monoterpene found in Lavender that works through the GABAergic system to promote inhibition of neuronal activity.

B-Myrcene is a natural muscle relaxant that is known to promote the “couch-lock” sedative effect in some cannabis strains. Researchers studying the habits of insomniacs noted that sleep occurred when subjects underwent a bedtime ritual that included relaxing the body, which invariably promotes the inhibitory networks involved in onset sleep latency.

 

 

References

 

  1. De Kloet, E. R., Joëls, M., & Holsboer, F. (2005). Stress and the brain: from adaptation to disease. Nature Reviews Neuroscience, 6(6), 463-475. doi:10.1038/nrn1683
  2. Bystritsky, Alexander et al. “Current diagnosis and treatment of anxiety disorders” P & T : a peer-reviewed journal for formulary management vol. 38,1 (2013): 30-57.
  3. Harvard Health Publishing. "Understanding the Stress Response." Harvard Health. Accessed March 19, 2019. https://www.health.harvard.edu/staying-healthy/understanding-the-stress-response.
  4. Whirledge, S., & Cidlowski, J. A. (2010). Glucocorticoids, stress, and fertility. Minerva endocrinologica, 35(2), 109-25.
  5. Smith, S. M., & Vale, W. W. (2006). The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues in clinical neuroscience, 8(4), 383-95.
  6. Panossian, Alexander, and Georg Wikman. "Effects of Adaptogens on the Central Nervous System and the Molecular Mechanisms Associated with Their Stress—Protective Activity." Pharmaceuticals 3, no. 1 (2010): 188-224. doi:10.3390/ph3010188.
  7. Bouayed, Jaouad. "Relationship Between Oxidative Stress and Anxiety: Emerging Role of Antioxidants Within Therapeutic or Preventive Approaches." Anxiety Disorders, 2011. doi:10.5772/19214.
  8. Salim, Samina. "Oxidative Stress and Psychological Disorders." Current Neuropharmacology 12, no. 2 (2014): 140-47. doi:10.2174/1570159x11666131120230309.
  9. Hassan, Waseem, Carlos Barroso Silva, Imdad Ullah Mohammadzai, Joao Teixeira Da Rocha, and J. Landeira-Fernandez. "Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions." Current Neuropharmacology 12, no. 2 (2014): 120-39. doi:10.2174/1570159x11666131120232135.
  10. Bouayed, Jaouad, Hassan Rammal, and Rachid Soulimani. "Oxidative Stress and Anxiety: Relationship and Cellular Pathways." Oxidative Medicine and Cellular Longevity 2, no. 2 (2009): 63-67. doi:10.4161/oxim.2.2.7944.
  11. Pratte, Morgan A., Kaushal B. Nanavati, Virginia Young, and Christopher P. Morley. "An Alternative Treatment for Anxiety: A Systematic Review of Human Trial Results Reported for the Ayurvedic Herb Ashwagandha (Withania Somnifera)." The Journal of Alternative and Complementary Medicine 20, no. 12 (2014): 901-08. doi:10.1089/acm.2014.0177.
  12. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Chandrasekhar, K., Kapoor, J., & Anishetty, S. (2012). Indian journal of psychological medicine, 34(3), 255.
  13. Mishra, MD, PhD, L., Singh, PhD, B., & Dagenais, BA, S. (2000). Scientific Basis for the Therapeutic Use of Withania somnifera (Ashwagandha): A Review. Alternative Medicine Review, 4(5), 344-346.  
  14. Bhattacharya, S. K., Satyan, K. S., & Ghosal, S. (1997). Antioxidant activity of glycowithanolides from Withania somnifera. Indian Journal of Experimental Biology, 35, 236-239.  
  15. PANDA, S., &  KAR, A. (1997). Evidence for free radical scavenging activity of Ashwagandha root powder in mice. Indian J Physiol Pharmacol, 41(4), 424-426.
  16. Nathan, Pradeep J., Kristy Lu, M. Gray, and C. Oliver. "The Neuropharmacology of L-Theanine (N-Ethyl-L-Glutamine)." Journal of Herbal Pharmacotherapy 6, no. 2 (2006): 21-30. doi:10.1080/j157v06n02_02.
  17. White, D., Klerk, S., Woods, W., Gondalia, S., Noonan, C., & Scholey, A. (2016). Anti-Stress, Behavioural and Magnetoencephalography Effects of an l-Theanine-Based Nutrient Drink: A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial. Nutrients. doi:10.3390/nu8010053 
  18. Nathan, P. J., Lu, K., Gray, M., & Oliver, C. (2006). The Neuropharmacology of L-Theanine(N-Ethyl-L-Glutamine). Journal of Herbal Pharmacotherapy, 6(2), 21-30. doi:10.1080/j157v06n02_02
  19. Lyon, M R, et al. “The Effects of L-Theanine (Suntheanine®) on Objective Sleep Quality in Boys with Attention Deficit Hyperactivity Disorder (ADHD): a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.” Current Neurology and Neuroscience Reports., U.S. National
  20. Nobre, A C, et al. “L-Theanine, a Natural Constituent in Tea, and Its Effect on Mental State.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/pubmed/18296328.
  21. Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., … Busatto, G. F. (2003). Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow. Neuropsychopharmacology, 29(2), 417-426. doi:10.1038/sj.npp.1300340
  22. Crippa, José Alexandre S, Guilherme Nogueira Derenusson, Thiago Borduqui Ferrari, Lauro Wichert-Ana, Fábio Ls Duran, Rocio Martin-Santos, Marcus Vinícius Simões, Sagnik Bhattacharyya, Paolo Fusar-Poli, Zerrin Atakan, Alaor Santos Filho, Maria Cecília Freitas-Ferrari, Philip K. Mcguire, Antonio Waldo Zuardi, Geraldo F. Busatto, and Jaime Eduardo Cecílio Hallak. "Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: A Preliminary Report." Journal of Psychopharmacology 25, no. 1 (2010): 121-30. doi:10.1177/0269881110379283.
  23. Fusar-Poli, Paolo, Paul Allen, Sagnik Bhattacharyya, José A. Crippa, Andrea Mechelli, Stefan Borgwardt, Rocio Martin-Santos, Marc L. Seal, Colin Ocarrol, Zerrin Atakan, Antonio W. Zuardi, and Philip Mcguire. "Modulation of Effective Connectivity during Emotional Processing by Δ9-tetrahydrocannabinol and Cannabidiol." The International Journal of Neuropsychopharmacology 13, no. 04 (2009): 421. doi:10.1017/s1461145709990617.
  24. Bergamaschi, M. M., Queiroz, R. H., Chagas, M. H., de Oliveira, D. C., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E., Zuardi, A. W., … Crippa, J. A. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 36(6), 1219-26.
  25. S P Banerjee, S H Snyder and R Mechoulam. “Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes.” Journal of Pharmacology and Experimental Therapeutics July 1975, 194 (1) 74-81.
  26. Minihane, Anne M., Sophie Vinoy, Wendy R. Russell, Athanasia Baka, Helen M. Roche, Kieran M. Tuohy, Jessica L. Teeling, Ellen E. Blaak, Michael Fenech, David Vauzour, Harry J. Mcardle, Bas H. A. Kremer, Luc Sterkman, Katerina Vafeiadou, Massimo Massi Benedetti, Christine M. Williams, and Philip C. Calder. "Low-grade Inflammation, Diet Composition and Health: Current Research Evidence and Its Translation." British Journal of Nutrition 114, no. 07 (2015): 999-1012. doi:10.1017/s0007114515002093.
  27. Haroyan, Armine, Vahan Mukuchyan, Nana Mkrtchyan, Naira Minasyan, Srbuhi Gasparyan, Aida Sargsyan, Mikael Narimanyan, and Areg Hovhannisyan. "Efficacy and Safety of Curcumin and Its Combination with Boswellic Acid in Osteoarthritis: A Comparative, Randomized, Double-blind, Placebo-controlled Study." BMC Complementary and Alternative Medicine 18, no. 1 (2018). doi:10.1186/s12906-017-2062-z.
  28. Nagarkatti, Prakash, Rupal Pandey, Sadiye Amcaoglu Rieder, Venkatesh L. Hegde, and Mitzi Nagarkatti. "Cannabinoids as Novel Anti-inflammatory Drugs." Future Medicinal Chemistry 1, no. 7 (2009): 1333-349. doi:10.4155/fmc.09.93.
  29. Maione, Sabatino, Fabiana Piscitelli, Luisa Gatta, Daniela Vita, Luciano De Petrocellis, Enza Palazzo, Vito De Novellis, and Vincenzo Di Marzo. "Non-psychoactive Cannabinoids Modulate the Descending Pathway of Antinociception in Anaesthetized Rats through Several Mechanisms of Action." British Journal of Pharmacology 162, no. 3 (2011): 584-96. doi:10.1111/j.1476-5381.2010.01063.x.
  30. Koivisto, Ari, Niina Jalava, Raymond Bratty, and Antti Pertovaara. "TRPA1 Antagonists for Pain Relief." Pharmaceuticals 11, no. 4 (2018): 117. doi:10.3390/ph11040117.
  31. Gugliandolo, Agnese, Federica Pollastro, Gianpaolo Grassi, Placido Bramanti, and Emanuela Mazzon. "In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid." International Journal of Molecular Sciences 19, no. 7 (2018): 1992. doi:10.3390/ijms19071992.
  32. Sengupta, Krishanu, Krishnaraju V. Alluri, Andey Satish, Simanchala Mishra, Trimurtulu Golakoti, Kadainti Vs Sarma, Dipak Dey, and Siba P. Raychaudhuri. "A Double Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of 5-Loxin® for Treatment of Osteoarthritis of the Knee." Arthritis Research & Therapy 10, no. 4 (2008). doi:10.1186/ar2461.
  33. Ammon, H. (2010). Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytomedicine,17(11), 862-867. doi:10.1016/j.phymed.2010.03.003
  34. Haroyan, Armine, Vahan Mukuchyan, Nana Mkrtchyan, Naira Minasyan, Srbuhi Gasparyan, Aida Sargsyan, Mikael Narimanyan, and Areg Hovhannisyan. "Efficacy and Safety of Curcumin and Its Combination with Boswellic Acid in Osteoarthritis: A Comparative, Randomized, Double-blind, Placebo-controlled Study." BMC Complementary and Alternative Medicine 18, no. 1 (2018). doi:10.1186/s12906-017-2062-z.
  35. Daily, James W., Mini Yang, and Sunmin Park. "Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials." Journal of Medicinal Food 19, no. 8 (2016): 717-29. doi:10.1089/jmf.2016.3705.
  36. Gautam, S. C., Gao, X., & Dulchavsky, S. (n.d.). IMMUNOMODULATION BY CURCUMIN. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, 321-341. doi:10.1007/978-0-387-46401-5_14
  37. Funk, J. L., Oyarzo, J. N., Frye, J. B., Chen, G., Lantz, R. C., Jolad, S. D., … Timmermann, B. N. (2006). Turmeric Extracts Containing Curcuminoids Prevent Experimental Rheumatoid Arthritis. Journal of Natural Products, 69(3), 351-355. doi:10.1021/np050327j 
  38. Park, S. J., Garcia, C. V., Shin, G. H., & Kim, J. T. (2018). Improvement of curcuminoid bioaccessibility from turmeric by a nanostructured lipid carrier system. Food Chemistry, 251, 51-57. doi:10.1016/j.foodchem.2018.01.071
  39. Baird, L., & Dinkova-Kostova, A. T. (2011). The cytoprotective role of the Keap1–Nrf2 pathway. Archives of Toxicology, 85(4), 241-272. doi:10.1007/s00204-011-0674-5
  40. Grzanna, R., Lindmark, L., & Frondoza, C. G. (2005). Ginger—An Herbal Medicinal Product with Broad Anti-Inflammatory Actions. Journal of Medicinal Food, 8(2), 125-132. doi:10.1089/jmf.2005.8.125
  41. Shephard, R. (2011). Ginger (Zingiber officinale) Reduces Muscle Pain Caused by Eccentric Exercise. Yearbook of Sports Medicine, 2011, 179-181. doi:10.1016/s0162-0908(10)79790-7
  42. Lantz, R., Chen, G., Sarihan, M., Sólyom, A., Jolad, S., & Timmermann, B. (2007). The effect of extracts from ginger rhizome on inflammatory mediator production. Phytomedicine, 14(2-3), 123-128. doi:10.1016/j.phymed.2006.03.003
  43. Mashhadi, N. S., Ghiasvand, R., Askari, G., Hariri, M., Darvishi, L., & Mofid, M. R. (2013). Anti-oxidative and anti-inflammatory effects of ginger in health and physical activity: review of current evidence. International journal of preventive medicine, 4(Suppl 1), S36–S42. 
  44. Kesarwani, K., & Gupta, R. (2013). Bioavailability enhancers of herbal origin: An overview. Asian Pacific Journal of Tropical Biomedicine, 3(4), 253-266. doi:10.1016/s2221-1691(13)60060-x
  45. Rufino, Ana T., Madalena Ribeiro, Fernando Judas, Lígia Salgueiro, Maria C. Lopes, Carlos Cavaleiro, and Alexandrina F. Mendes. "Anti-inflammatory and Chondroprotective Activity of ( )-α-Pinene: Structural and Enantiomeric Selectivity." Journal of Natural Products 77, no. 2 (2014): 264-69. doi:10.1021/np400828x.
  46. Araújo-Filho, Heitor G., Erik W.m. Pereira, Marília M. Rezende, Paula P. Menezes, Adriano A.s. Araújo, Rosana S.s. Barreto, Anita O.b.p.b. Martins, Thaís R. Albuquerque, Bruno A.f. Silva, Isabel S. Alcantara, Henrique D.m. Coutinho, Irwin R.a. Menezes, Lucindo J. Quintans-Júnior, and Jullyana S.s. Quintans. "D-limonene Exhibits Superior Antihyperalgesic Effects in a β -cyclodextrin-complexed Form in Chronic Musculoskeletal Pain Reducing Fos Protein Expression on Spinal Cord in Mice." Neuroscience 358 (2017): 158-69. doi:10.1016/j.neuroscience.2017.06.037.
  47. Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH, Karsak M, Zimmer A.
  48. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9099-104. doi: 10.1073/pnas.0803601105. Epub 2008 Jun 23.
  49. Shannon, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente Journal. doi:10.7812/tpp/18-041
  50. Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for Sleep: A Systematic Review and Meta-Analysis. The American Journal of Medicine, 119(12), 1005-1012. doi:10.1016/j.amjmed.2006.02.026
  51. Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2009). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. British Journal of Pharmacology, 159(1), 122-128. doi:10.1111/j.1476-5381.2009.00521.x
  52. Bakas, T., Van Nieuwenhuijzen, P., Devenish, S., McGregor, I., Arnold, J., & Chebib, M. (2017). The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. Pharmacological Research, 119, 358-370. doi:10.1016/j.phrs.2017.02.022
  53. Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proceedings of the National Academy of Sciences, 103(20), 7895-7900. doi:10.1073/pnas.0511232103
  54. Lyon, M. R., Kapoor, M. P., & Juneja, L. R. (2011). The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. Altern Med Rev. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22214254
  55. White, D., Klerk, S., Woods, W., Gondalia, S., Noonan, C., & Scholey, A. (2016). Anti-Stress, Behavioural and Magnetoencephalography Effects of an l-Theanine-Based Nutrient Drink: A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial. Nutrients. doi:10.3390/nu8010053
  56. The Mechanism of Action for Valerian (Valeriana officinalis) In the Treatment of Insomnia. (n.d.). Retrieved from https://www.ebmconsult.com/articles/valerian-valeriana-officinalis-treating-insomnia-sleep
  57. Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for Sleep: A Systematic Review and Meta-Analysis. The American Journal of Medicine, 119(12), 1005-1012. doi:10.1016/j.amjmed.2006.02.026 
  58. Becker, A., Felgentreff, F., Schröder, H., Meier, B., & Brattström, A. (2014). The anxiolytic effects of a Valerian extract is based on Valerenic acid. BMC Complementary and Alternative Medicine, 14(1). doi:10.1186/1472-6882-14-267 
  59. Jung, H. Y., Yoo, D. Y., Nam, S. M., Kim, J. W., Choi, J. H., Yoo, M., … Hwang, I. K. (2015). Valerenic Acid Protects Against Physical and Psychological Stress by Reducing the Turnover of Serotonin and Norepinephrine in Mouse Hippocampus-Amygdala Region. Journal of Medicinal Food, 18(12), 1333-1339. doi:10.1089/jmf.2014.3412 
  60. Murphy, K., Kubin, Z., Shepherd, J., & Ettinger, R. (2010). Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine, 17(8-9), 674-678. doi:10.1016/j.phymed.2009.10.020
  61. Carnevale, G., Di Viesti, V., Zavatti, M., & Zanoli, P. (2011). Anxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats. Phytomedicine, 18(10), 848-851. doi:10.1016/j.phymed.2011.01.016
  62. Better Sleep with 5-HTP. (2017, October 12). Retrieved from https://www.psychologytoday.com/us/blog/sleep-newzzz/201710/better-sleep-5-htp
  63. Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J., Xie, X., … Altmann, K. (n.d.). Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A. doi:10.1073/pnas.0803601105
  64. Milanos, S., Elsharif, S. A., Janzen, D., Buettner, A., & Villmann, C. (2017). Metabolic Products of Linalool and Modulation of GABAA Receptors. Frontiers in Chemistry, 5. doi:10.3389/fchem.2017.00046
  65. Gurgel do Vale, T., Couto Furtado, E., Santos, J., & Viana, G. (2002). Central effects of citral, myrcene and limonene, constituents of essential oil chemotypes from Lippia alba (Mill.) N.E. Brown. Phytomedicine9